Identifying one antibody
18 min
- Use antigen-positive nonreactive cells for valid antibody exclusions
Try first
Get the idea
Cross out, then name
An antibody panel tests the patient's plasma against 8 to 16 group O cells, each with its antigens listed on the lot's antigram. The bench works it in two passes.1,2
- Take a nonreactive cell. The plasma holds no detectable antibody against the antigens that cell carries.
- Cross out each antigen that cell carries in a form the antibody would detect.
- Repeat for every nonreactive cell.
- Compare what is still standing with the reactive cells. The antigen whose pattern matches the reactions is the antibody.
Double-dose cells
Antibodies to C, c, E, e, Jka, Jkb, Fya, Fyb, M, N, S and s often show dosage. They react more strongly with cells that carry a double dose of the antigen, and a weak example can miss a single dose.3,4 Under the usual exclusion rule, cross out one of these antigens only on a nonreactive cell that carries it without its partner, such as Jk(a+b−) for Jka. D, K, k, P1, Lea and Leb are crossed out on any nonreactive cell that carries them. Your laboratory's validated exclusion rule sets the details.2
An antigen that no suitable nonreactive cell carries stays standing. Selected cells from another lot, or the patient's own antigen type, settle it.2
Confirming the answer
A presumptive specificity needs two checks.2,5
- The rule of three. At least three reactive cells carry the antigen, and at least three nonreactive cells lack it.
- The patient's phenotype. The patient's red cells lack the antigen. Recent transfusion or a positive DAT can make this typing unreliable, and genotyping may be needed.
The patient then receives red cells negative for the antigen, crossmatched through the antiglobulin phase.2
References
- Testing of source material, 21 CFR §660.33 (2026). Accessed September 27, 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-660/subpart-D/section-660.33
- Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
- Immucor, Inc. Panoscreen Reagent Red Blood Cells Package Insert. US Food and Drug Administration. Accessed September 27, 2026.
- Raman L, Armstrong B, Smart E. Principles of laboratory techniques. ISBT Sci Ser. 2020;15(suppl 1):81-111. doi:10.1111/voxs.12591
- Manduzio P. Alloantibody identification: the importance of temperature, strength reaction and enzymes—a practical approach. Hematol Rep. 2024;16(4):815-824. doi:10.3390/hematolrep16040077
Watch one
Marguerite Haddad, 45, has a reactive antibody screen before a hysterectomy. Her panel reads:
Which antibody is present?
| Cell | D | C | E | c | e | K | k | Fya | Fyb | Jka | Jkb | M | N | S | s | P1 | Lea | Leb | IS | 37 | AHG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | 0 | 0 | + | + | + | + | + | + | + | + | + | 0 | + | + | 0 | + | 0 | 0 | 1+ |
| 2 | + | + | 0 | 0 | + | 0 | + | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | 0 | 0 | 0 | 0 |
| 3 | + | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | + | 0 | + | 0 | 0 | 2+ |
| 4 | + | 0 | 0 | + | + | 0 | + | 0 | 0 | + | 0 | + | + | 0 | + | + | 0 | 0 | 0 | 0 | 0 |
| 5 | 0 | + | 0 | + | + | 0 | + | + | 0 | 0 | + | + | 0 | + | + | 0 | 0 | + | 0 | 0 | 2+ |
| 6 | 0 | 0 | + | + | + | 0 | + | 0 | + | + | + | 0 | + | 0 | + | + | 0 | + | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | + | + | + | + | + | 0 | + | 0 | + | 0 | + | 0 | + | + | 0 | 0 | 0 | 2+ |
| 8 | 0 | 0 | 0 | + | + | 0 | + | 0 | + | 0 | + | + | + | + | + | + | 0 | + | 0 | 0 | 0 |
| 9 | 0 | 0 | 0 | + | + | + | + | 0 | + | + | + | 0 | + | 0 | + | 0 | 0 | + | 0 | 0 | 0 |
| 10 | + | + | 0 | + | + | 0 | + | + | 0 | 0 | + | + | + | + | + | + | 0 | + | 0 | 0 | 2+ |
| 11 | + | 0 | + | + | 0 | 0 | + | 0 | + | + | 0 | + | 0 | 0 | + | + | + | 0 | 0 | 0 | 0 |
| Autocontrol | 0 | 0 | 0 |
- Check the autocontrol. It is 0 in every phase.
A nonreactive autocontrol favors an alloantibody over an autoantibody.
- Note the phase. Every reaction is at the antiglobulin phase.
IgG antibodies such as Rh, Kell, Kidd and Duffy react at the antiglobulin phase.
- Cross out on the nonreactive cells 2, 4, 6, 8, 9 and 11. Every antigen except Fya falls on one of them.
A nonreactive cell shows no detectable antibody against what it carries.
- Check the dosage antigens. E falls only on cell 11, which is E+e−, and Jkb only on cell 8, which is Jk(a−b+). Both are double-dose cells, so both crossings stand.
A single-dose cell could miss a weak antibody that shows dosage.
- Match the pattern. Fya is on cells 1, 3, 5, 7 and 10, the five reactive cells. Cell 1 is Fy(a+b+) and reacts 1+, and the double-dose cells react 2+, which fits a Duffy antibody.
Every reactive cell must carry the antibody's antigen.
- Confirm. Five reactive Fy(a+) cells and six nonreactive Fy(a−) cells meet the rule of three. Type her red cells for Fya.
An alloantibody forms only against an antigen the patient lacks.
Your turn
Use it
- Esperanza Nwosu, 52, a choir director who hums through her blood draws, MRN 3319826, has a reactive antibody screen.
- Her knee replacement is in 3 days.
- She has had two pregnancies and no transfusions.
- Her panel's autocontrol is nonreactive.
| Cell | D | C | E | c | e | K | k | Fya | Fyb | Jka | Jkb | M | N | S | s | P1 | Lea | Leb | IS | 37 | AHG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | + | 0 | 0 | + | + | + | + | + | + | + | + | + | 0 | + | + | 0 | + | 0 | 0 | 0 |
| 2 | + | + | 0 | 0 | + | 0 | + | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | 0 | 0 | 0 | 2+ |
| 3 | + | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | + | 0 | 0 | + | + | 0 | + | 0 | 0 | 0 |
| 4 | + | 0 | 0 | + | + | 0 | + | 0 | 0 | + | 0 | + | + | 0 | + | + | 0 | 0 | 0 | 0 | 0 |
| 5 | 0 | + | 0 | + | + | 0 | + | + | 0 | 0 | + | + | 0 | + | + | 0 | 0 | + | 0 | 0 | 1+ |
| 6 | 0 | 0 | + | + | + | 0 | + | 0 | + | + | + | 0 | + | 0 | + | + | 0 | + | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | + | + | + | + | + | 0 | + | 0 | + | 0 | + | 0 | + | + | 0 | 0 | 0 | 2+ |
| 8 | 0 | 0 | 0 | + | + | 0 | + | 0 | + | 0 | + | + | + | + | + | + | 0 | + | 0 | 0 | 1+ |
| 9 | 0 | 0 | 0 | + | + | + | + | 0 | + | + | + | 0 | + | 0 | + | 0 | 0 | + | 0 | 0 | 0 |
| 10 | + | + | 0 | + | + | 0 | + | + | 0 | 0 | + | + | + | + | + | + | 0 | + | 0 | 0 | 1+ |
| 11 | + | 0 | + | + | 0 | 0 | + | 0 | + | + | 0 | + | 0 | 0 | + | + | + | 0 | 0 | 0 | 0 |
| Autocontrol | 0 | 0 | 0 |
The clue that settled this case is every reactive cell carrying S, with every other antigen crossed out on a suitable nonreactive cell. Her S-negative type then confirms anti-S, and S-negative units follow.
Results
- Use antigen-positive nonreactive cells for valid antibody exclusions
To review
6 questions from this step will come back in Review.
Next step: Two antibodies, the autocontrol and enzymesReview nowOpen the part
Keep
Sources checked
The rest of this step
A short briefing, a demonstration at the bench, 3 practice problems and a short case.
A free account opens the rest and keeps your progress.